These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23500542)

  • 1. Differential sensitivities of the vascular K(ATP) channel to various PPAR activators.
    Wang Y; Yu L; Cui N; Jin X; Zhu D; Jiang C
    Biochem Pharmacol; 2013 May; 85(10):1495-503. PubMed ID: 23500542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone selectively inhibits K(ATP) channels by acting on the K(IR) 6 subunit.
    Yu L; Jin X; Cui N; Wu Y; Shi Z; Zhu D; Jiang C
    Br J Pharmacol; 2012 Sep; 167(1):26-36. PubMed ID: 22394376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
    Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
    Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
    Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
    Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.
    Li AC; Binder CJ; Gutierrez A; Brown KK; Plotkin CR; Pattison JW; Valledor AF; Davis RA; Willson TM; Witztum JL; Palinski W; Glass CK
    J Clin Invest; 2004 Dec; 114(11):1564-76. PubMed ID: 15578089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline.
    Yu L; Jin X; Yang Y; Cui N; Jiang C
    Br J Pharmacol; 2011 Dec; 164(8):2064-72. PubMed ID: 21671900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome-proliferator-activated receptors γ and β/δ mediate vascular endothelial growth factor production in colorectal tumor cells.
    Röhrl C; Kaindl U; Koneczny I; Hudec X; Baron DM; König JS; Marian B
    J Cancer Res Clin Oncol; 2011 Jan; 137(1):29-39. PubMed ID: 20221637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone.
    Wang XJ; Zhang J; Wang SQ; Xu WR; Cheng XC; Wang RL
    Drug Des Devel Ther; 2014; 8():2255-62. PubMed ID: 25422585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor-β/δ, the acute signaling factor in prostacyclin-induced pulmonary vasodilation.
    Li Y; Connolly M; Nagaraj C; Tang B; Bálint Z; Popper H; Smolle-Juettner FM; Lindenmann J; Kwapiszewska G; Aaronson PI; Wohlkoenig C; Leithner K; Olschewski H; Olschewski A
    Am J Respir Cell Mol Biol; 2012 Mar; 46(3):372-9. PubMed ID: 22021335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor γ/δ agonists.
    Gim HJ; Li H; Jeong JH; Lee SJ; Sung MK; Song MY; Park BH; Oh SJ; Ryu JH; Jeon R
    Bioorg Med Chem; 2015 Jul; 23(13):3322-36. PubMed ID: 25982078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1α,25-dihydroxyvitamin D3 and rosiglitazone synergistically enhance osteoblast-mediated mineralization.
    Woeckel VJ; Bruedigam C; Koedam M; Chiba H; van der Eerden BC; van Leeuwen JP
    Gene; 2013 Jan; 512(2):438-43. PubMed ID: 22967709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
    Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
    PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPAR-alpha and PPAR-beta expression changes in the hippocampus of rats undergoing global cerebral ischemia/reperfusion due to PPAR-gamma status.
    Luo Y; He Q; Kuang G; Jiang Q; Yang J
    Behav Brain Funct; 2014 Jun; 10(1):21. PubMed ID: 24934302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.
    Han L; Shen WJ; Bittner S; Kraemer FB; Azhar S
    Future Cardiol; 2017 May; 13(3):279-296. PubMed ID: 28581362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring Solution Structures of Peroxisome Proliferator-Activated Receptor β/δ upon Ligand Binding.
    Schwarz R; Tänzler D; Ihling CH; Sinz A
    PLoS One; 2016; 11(3):e0151412. PubMed ID: 26992147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel benefits of peroxisome proliferator-activated receptors on cardiovascular risk.
    Millar JS
    Curr Opin Lipidol; 2013 Jun; 24(3):233-8. PubMed ID: 23594710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors.
    Krönke G; Kadl A; Ikonomu E; Blüml S; Fürnkranz A; Sarembock IJ; Bochkov VN; Exner M; Binder BR; Leitinger N
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1276-82. PubMed ID: 17413033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multitargeted bioactive ligands for PPARs discovered in the last decade.
    Zhang J; Liu X; Xie XB; Cheng XC; Wang RL
    Chem Biol Drug Des; 2016 Nov; 88(5):635-663. PubMed ID: 27317624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
    Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor β/δ and γ agonists differentially affect prostaglandin E2 and cytokine synthesis and nutrient transporter expression in porcine trophoblast cells during implantation.
    Blitek A; Szymanska M
    Theriogenology; 2020 Aug; 152():36-46. PubMed ID: 32361305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.